scholarly article | Q13442814 |
P50 | author | Hans Lassmann | Q35704729 |
Finn Sellebjerg | Q59546273 | ||
P2093 | author name string | R Horuk | |
R M Ransohoff | |||
C Trebst | |||
P Kivisäkk | |||
M K Cathcart | |||
J Hesselgesser | |||
T L Sørensen | |||
P2860 | cites work | Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis | Q24297982 |
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients | Q24563395 | ||
Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis | Q28293364 | ||
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
Axonal transection in the lesions of multiple sclerosis | Q29615585 | ||
Chemokines: a new classification system and their role in immunity | Q29615663 | ||
Chemokines--chemotactic cytokines that mediate inflammation | Q29616433 | ||
The cysteine-cysteine family of chemokines RANTES, MIP-1alpha, and MIP-1beta induce trypanocidal activity in human macrophages via nitric oxide | Q33764616 | ||
Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1 | Q33784182 | ||
beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi | Q34001865 | ||
New diagnostic criteria for multiple sclerosis: guidelines for research protocols | Q34271601 | ||
Demyelinating optic neuritis: clinical features and differential diagnosis. | Q37779346 | ||
CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons | Q39066033 | ||
Pretreatment of plastic petri dishes with fetal calf serum. A simple method for macrophage isolation | Q39689060 | ||
Expression and complex assembly of calcium-binding proteins MRP8 and MRP14 during differentiation of murine myelomonocytic cells | Q41588196 | ||
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group | Q41735091 | ||
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain | Q41778413 | ||
The CCR5 deletion mutation fails to protect against multiple sclerosis | Q44279950 | ||
Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis | Q48048028 | ||
Lesion development in Marburg's type of acute multiple sclerosis: from inflammation to demyelination | Q48160881 | ||
Oligodendrocytes in the early course of multiple sclerosis | Q48196640 | ||
Monocyte/macrophage differentiation in early multiple sclerosis lesions | Q48752790 | ||
Axonal damage in acute multiple sclerosis lesions | Q48776354 | ||
CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells | Q56880736 | ||
Macrophages in multiple sclerosis | Q61709749 | ||
CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis | Q63728112 | ||
Macrophage inflammatory protein 1 modulates macrophage function | Q68107144 | ||
Activation of dual T cell signaling pathways by the chemokine RANTES | Q71768178 | ||
An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis | Q71829114 | ||
Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation | Q73822019 | ||
MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation | Q73867325 | ||
Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent | Q74165253 | ||
Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages | Q74173208 | ||
Etiology and pathogenesis of multiple sclerosis | Q77563027 | ||
Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1 | Q77900081 | ||
Interferon-gamma upregulates CCR5 expression in cord and adult blood mononuclear phagocytes | Q78015744 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple sclerosis | Q8277 |
nervous system | Q9404 | ||
patient | Q181600 | ||
P304 | page(s) | 1701-1710 | |
P577 | publication date | 2001-11-01 | |
P1433 | published in | The American Journal of Pathology | Q4744259 |
P1476 | title | CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis | |
P478 | volume | 159 |
Q38587668 | A basic overview of multiple sclerosis immunopathology |
Q34389532 | A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation |
Q50695778 | Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. |
Q92314304 | An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders |
Q37683772 | Anti-chemokine small molecule drugs: a promising future? |
Q80884999 | Association of haplotypes in the beta-chemokine locus with multiple sclerosis |
Q36515946 | Brain endothelial dysfunction in cerebral adrenoleukodystrophy |
Q35748920 | CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages |
Q36196440 | CCR1 antagonists in clinical development |
Q38702121 | CCR5 blockade for neuroinflammatory diseases--beyond control of HIV. |
Q35693333 | CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques |
Q36497113 | CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro |
Q48328342 | CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. |
Q48962767 | CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. |
Q90732168 | Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells |
Q33905233 | Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1. |
Q36072420 | Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions |
Q36241739 | Chemokine receptor CXCR3: an unexpected enigma |
Q37481238 | Chemokine receptor antagonists: Part 1. |
Q37349685 | Chemokine receptor antagonists: overcoming developmental hurdles |
Q37481304 | Chemokine receptor antagonists: part 2. |
Q34131442 | Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNgamma-producing effector cells |
Q47366191 | Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). |
Q48829652 | Chemokines and chemokine receptors in inflammation of the CNS. |
Q48651342 | Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. |
Q36963161 | Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? |
Q27687402 | Chemokines and chemokine receptors: update on utility and challenges for the clinician |
Q35771258 | Chemokines and glial cells: a complex network in the central nervous system. |
Q35196338 | Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. |
Q48701331 | Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment |
Q89684473 | Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis |
Q26740330 | Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis |
Q38771884 | Dendritic cells as therapeutic targets in neuroinflammation |
Q59333230 | Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid |
Q33841113 | Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis |
Q30585165 | Differential roles of microglia and monocytes in the inflamed central nervous system |
Q26749131 | Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models |
Q99711187 | Dynamic Responses of Microglia in Animal Models of Multiple Sclerosis |
Q44598110 | Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. |
Q35581158 | Emerging disease modifying therapies for multiple sclerosis |
Q36868435 | Emerging therapies for MS. |
Q92856694 | Entanglement of CCR5 and Alzheimer's Disease |
Q89493546 | Environmental Influencers, MicroRNA, and Multiple Sclerosis |
Q90644569 | Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1 |
Q53099338 | Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis. |
Q73454688 | Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals |
Q47846958 | Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions |
Q34462248 | Functional expression of chemokine receptor CCR5 on CD4(+) T cells during virus-induced central nervous system disease |
Q37112554 | G protein-coupled receptors as therapeutic targets for multiple sclerosis |
Q34532418 | Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients |
Q33221007 | Haplotypes within genes of beta-chemokines in 17q11 are associated with multiple sclerosis: a second phase study |
Q73308674 | IL-10 synergistically enhances GM-CSF-induced CCR1 expression in myelomonocytic cells |
Q36054797 | Immunologic correlates of MS pathologic subtypes |
Q33775611 | Increased Transendothelial Transport of CCL3 Is Insufficient to Drive Immune Cell Transmigration through the Blood-Brain Barrier under Inflammatory Conditions In Vitro. |
Q39743749 | Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues. |
Q48003021 | Induction of glial L-CCR mRNA expression in spinal cord and brain in experimental autoimmune encephalomyelitis |
Q45406699 | Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients |
Q92083363 | Influence of Chemokine N-Terminal Modification on Biased Agonism at the Chemokine Receptor CCR1 |
Q36884649 | Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. |
Q60919677 | Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity |
Q54572718 | Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. |
Q37432097 | International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors |
Q30724821 | Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway |
Q24801279 | Involvement of beta-chemokines in the development of inflammatory demyelination |
Q27691411 | It's a cell-eat-cell world: autophagy and phagocytosis. |
Q36768701 | Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination. |
Q38800732 | Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment |
Q42228175 | Longitudinal analysis of activation markers on monocyte subsets during the development of simian immunodeficiency virus encephalitis |
Q44412466 | Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. |
Q50982264 | Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis. |
Q38222226 | Macrophage subsets and microglia in multiple sclerosis |
Q37301528 | Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype |
Q38201907 | Macrophages: a double-edged sword in experimental autoimmune encephalomyelitis |
Q38182524 | Mechanisms of white matter damage in multiple sclerosis |
Q35167056 | Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis. |
Q36430868 | Microarray analysis in B cells among siblings with/without MS - role for transcription factor TCF2. |
Q26798185 | Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In Vivo |
Q48683454 | Migration of monocytes after intracerebral injection at entorhinal cortex lesion site |
Q37033330 | Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease |
Q29620067 | Monocyte recruitment during infection and inflammation |
Q26770661 | Multiple Sclerosis between Genetics and Infections: Human Endogenous Retroviruses in Monocytes and Macrophages |
Q61709654 | Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system |
Q34089994 | Multiple sclerosis: distribution of inflammatory cells in newly forming lesions |
Q80171702 | Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype |
Q24645165 | Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1 |
Q34743328 | New therapeutics that modulate chemokine networks |
Q43189651 | No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients. |
Q38029278 | Oligodendrocytes and the early multiple sclerosis lesion |
Q46441158 | Overcoming hurdles in developing successful drugs targeting chemokine receptors |
Q40697276 | Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta |
Q36410286 | Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes. |
Q48266534 | Pivotal Role for CD16+ Monocytes in Immune Surveillance of the Central Nervous System |
Q34117705 | Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta |
Q37362453 | Promiscuous drugs as therapeutics for chemokine receptors |
Q39282122 | Protective autoimmunity functions by intracranial immunosurveillance to support the mind: The missing link between health and disease |
Q40622118 | Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage inflammatory protein-1alpha) |
Q35753458 | Remyelinating and neuroprotective treatments in multiple sclerosis |
Q35669020 | SIV encephalitis lesions are composed of CD163(+) macrophages present in the central nervous system during early SIV infection and SIV-positive macrophages recruited terminally with AIDS. |
Q34503137 | Secondary progressive multiple sclerosis: current knowledge and future challenges |
Q46692323 | Synthesis and characterization of tritium labeled N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide |
Q64061544 | Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis |
Q35825040 | Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. |
Q38035711 | The anatomical and cellular basis of immune surveillance in the central nervous system. |
Q28299076 | The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting |
Q46705661 | The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis |
Q36490829 | The formation of inflammatory demyelinated lesions in cerebral white matter. |
Q24597958 | The innate immune system in demyelinating disease |
Q38236315 | The plasticity of inflammatory monocyte responses to the inflamed central nervous system. |
Q35031901 | The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). |
Q42208932 | The role of chemokines in acute liver injury |
Q37706120 | The role of dendritic cells in CNS autoimmunity |
Q38035240 | The role of regulatory T cells in neurodegenerative diseases |
Q36586942 | Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions |
Q37780481 | Transgenic mouse models of multiple sclerosis |
Q44050707 | Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. |
Q34076041 | Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation |
Q47639897 | Western lifestyle and immunopathology of multiple sclerosis |
Q79151474 | [Chemokine--possible new options for the treatment of multiple sclerosis] |
Search more.